Table 2.
Comparison of HbA1c at Visit A (telehealth consultation during pandemic), Visit B (last face‐to‐face review prior to pandemic) and Visit C (face‐to‐face consultation 12 months earlier)
| HbA1c at Visit A, % (mmol/mol) (±SD) | HbA1c at Visit B, % (mmol/mol) (±SD) | HbA1c at Visit C, % (mmol/mol) (±SD) | |
|---|---|---|---|
| All patients (n = 504) |
7.8 ± 1.6 (62 ± 17) |
8.1 ± 1.4 (65 ± 15)** | 8.2 ± 1.7 (66 ± 19)** |
| Type 1 diabetes (n = 92) | 8.3 ± 1.4 (67 ± 15) | 8.4 ± 1.7 (68 ± 19) | 8.4 ± 1.8 (68 ± 20) |
| Type 2 diabetes (n = 412) | 7.8 ± 1.4 (62 ± 15) | 8.0 ± 1.6 (64 ± 17)* | 8.2 ± 1.7 (66 ± 19)** |
| Liverpool Hospital (n = 359) | 7.9 ± 1.5 (63 ± 16) | 8.1 ± 1.6 (65 ± 17) | 8.2 ± 1.7 (66 ± 19)* |
| Fairfield Hospital (n = 145) | 7.7 ± 1.2 (61 ± 13) | 8.0 ± 1.5 (64 ± 16)* | 8.2 ± 1.6 (66 ± 17)** |
| Anglo‐European (n = 259) | 7.9 ± 1.3 (63 ± 14) | 8.0 ± 1.4 (64 ± 15) | 8.2 ± 1.6 (66 ± 17)* |
| Non‐Anglo‐European (n = 245) | 7.7 ± 1.4 (61 ± 15) | 8.0 ± 1.8 (64 ± 20) | 8.1 ± 1.8 (65 ± 20)* |
| Need interpreters (n = 128) | 7.8 ± 1.3 (62 ± 14) | 8.0 ± 1.7 (64 ± 19) | 8.2 ± 1.7 (66 ± 19) |
| No interpreters (n = 376) | 7.9 ± 1.4 (63 ± 15) | 8.1 ± 1.6 (65 ± 17) | 8.2 ± 1.7 (66 ± 19) |
| No. patients with improved HbA1c | |||
| Visit A versus Visit B, n (%) | 269 (53.4); P = 0.284 | ||
| Visit A versus Visit C, n (%) | 276 (54.8); P = 0.130 | ||
*
P < 0.05 when compared with Visit A.
**
P < 0.001 when compared with Visit A.